drugset / Trial / NCT00435799

Evaluating Collagen Cross-Linking (CCL) Treatment in Norway

NCT00435799

Phase 2/3 Unknown 40 enrolled Ullevaal University Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess safety, efficacy and stability of riboflavin-UV induced cross-linking of corneal collagen in reducing the progression of keratecatasia and in improving visual acuity. This is the first Norwegian study concerning CCL.

Timeline

Start
2007-02
Primary completion
2009-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Riboflavin Other / unclassified Topical

Indications